Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Investigation of EpsA, OmpA, and Bap Genes among MDR and XDR Acinetobacter baumannii Isolates in Khorramabad, Iran

Author(s): Iman Poladi, Pegah Shakib, Shahnaz Halimi, Somayeh Delfani, Farzad Ebrahim Zadeh and Faranak Rezaei*

Volume 19, Issue 4, 2024

Published on: 11 January, 2024

Page: [307 - 314] Pages: 8

DOI: 10.2174/0127724344274260231220052526

Price: $65

Abstract

Background: Acinetobacter baumannii is an opportunistic hospital pathogen with high antibiotic resistance, and the ability to produce biofilm. This study aimed to investigate epsA, ompA, and bap genes involved in biofilm formation in MDR and XDR clinical isolates of Acinetobacter baumannii in Khorramabad, Iran.

Methods: In this study, 79 A. baumannii isolates were collected from various samples of the patients admitted to tertiary hospitals in Khorramabad city, Iran, between January and August 2019. After performing the semi-quantitative evaluation of biofilm production by microtiter plate assay, screening of isolates carrying epsA, ompA, and bap genes was done by PCR method. Finally, statistical analyses were conducted using SPSS 22.

Results: Among 79 A. baumannii isolates, 52% XDR, 40% MDR, and 16% non-XDRMDR isolates were found to be biofilm producers. All XDR and 94% MDR isolates had ompA and epsA genes, and bap genes were detected among > 80% of these isolates. Moreover, the presence of biofilm-related genes and biofilm production among non-XDRMDR isolates were less than among resistant isolates (p≤ 0.01).

Conclusion: Based on the results, biofilm production and simultaneous presence of epsA, ompA, and bap genes among MDR, and XDR A. baumannii isolates have been found to be significantly more than non-XDR-MDR isolates.

« Previous Next »
Graphical Abstract

[1]
Lee CR, Lee JH, Park M, et al. Biology of Acinetobacter baumannii: Pathogenesis, antibiotic resistance mechanisms, and prospective treatment options. Front Cell Infect Microbiol 2017; 7: 55.
[http://dx.doi.org/10.3389/fcimb.2017.00055] [PMID: 28348979]
[2]
Asif M, Alvi IA, Rehman SU. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist 2018; 11: 1249-60.
[http://dx.doi.org/10.2147/IDR.S166750] [PMID: 30174448]
[3]
Eijkelkamp BA, Stroeher UH, Hassan KA, Paulsen IT, Brown MH. Comparative analysis of surface-exposed virulence factors of Acinetobacter baumannii. BMC Genomics 2014; 15(1): 1020.
[http://dx.doi.org/10.1186/1471-2164-15-1020] [PMID: 25422040]
[4]
Skariyachan S, Taskeen N, Ganta M, Venkata Krishna B. Recent perspectives on the virulent factors and treatment options for multidrug-resistant Acinetobacter baumannii. Crit Rev Microbiol 2019; 45(3): 315-33.
[http://dx.doi.org/10.1080/1040841X.2019.1600472] [PMID: 31012772]
[5]
Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021; 10(3): 373.
[http://dx.doi.org/10.3390/pathogens10030373] [PMID: 33808905]
[6]
Vrancianu CO, Gheorghe I, Czobor IB, Chifiriuc MC. Antibiotic resistance profiles, molecular mechanisms and innovative treatment strategies of acinetobacter baumannii. Microorganisms 2020; 8(6): 935.
[http://dx.doi.org/10.3390/microorganisms8060935] [PMID: 32575913]
[7]
Eze E, Chenia H, El Zowalaty M. Acinetobacter baumannii biofilms: effects of physicochemical factors, virulence, antibiotic resistance determinants, gene regulation, and future antimicrobial treatments. Infect Drug Resist 2018; 11: 2277-99.
[http://dx.doi.org/10.2147/IDR.S169894] [PMID: 30532562]
[8]
Qi L, Li H, Zhang C, et al. Relationship between antibiotic resistance, biofilm formation, and biofilm-specific resistance in Acinetobacter baumannii. Front Microbiol 2016; 7: 483.
[http://dx.doi.org/10.3389/fmicb.2016.00483] [PMID: 27148178]
[9]
Mancilla-Rojano J, Castro-Jaimes S, Ochoa SA, et al. Whole-genome sequences of five Acinetobacter baumannii strains from a child with leukemia M2. Front Microbiol 2019; 10: 132.
[http://dx.doi.org/10.3389/fmicb.2019.00132] [PMID: 30787915]
[10]
Fattahian Y, Rasooli I, Mousavi Gargari SL, Rahbar MR, Darvish Alipour Astaneh S, Amani J. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb Pathog 2011; 51(6): 402-6.
[http://dx.doi.org/10.1016/j.micpath.2011.09.004] [PMID: 21946278]
[11]
Ghasemi E, Ghalavand Z, Goudarzi H, et al. Phenotypic and genotypic investigation of biofilm formation in clinical and environmental isolates of Acinetobacter baumannii. Arch Clin Infect Dis 2018; 13(4): e12914.
[http://dx.doi.org/10.5812/archcid.12914]
[12]
Joshua AA, Girija ASS, Ganesh PS, Priyadharsini JV. Distribution of Biofilm-associated Genes among Acinetobacter baumannii by in silico PCR. J Pharm Res Int 2021; 33(58A): 140-9.
[http://dx.doi.org/10.9734/jpri/2021/v33i58A34099]
[13]
Donadu MG, Mazzarello V, Cappuccinelli P, et al. Relationship between the biofilm-forming capacity and antimicrobial resistance in clinical Acinetobacter baumannii isolates: Results from a laboratory-based in vitro study. Microorganisms 2021; 9(11): 2384.
[http://dx.doi.org/10.3390/microorganisms9112384] [PMID: 34835509]
[14]
Gedefie A, Demsiss W, Belete MA, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: A review. Infect Drug Resist 2021; 14: 3711-9.
[http://dx.doi.org/10.2147/IDR.S332051] [PMID: 34531666]
[15]
Babaie Z, Delfani S, Rezaei F, Norolahi F, Mahdian S, Shakib P. Molecular detection of carbapenem resistance in Acinetobacter baumannii isolated from patients in khorramabad city, Iran. Infect Disord Drug Targets 2020; 20(4): 543-9.
[http://dx.doi.org/10.2174/1871526519666190517124314] [PMID: 31099322]
[16]
Girija As S, Priyadharsini JV. CLSI based antibiogram profile and the detection of MDR and XDR strains of Acinetobacter baumannii isolated from urine samples. Med J Islam Repub Iran 2019; 33: 3.
[http://dx.doi.org/10.47176/mjiri.33.3] [PMID: 31086782]
[17]
Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18(3): 268-81.
[http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x] [PMID: 21793988]
[18]
Zheljazkov VD, Cantrell CL, Tekwani B, Khan SI. Content, composition, and bioactivity of the essential oils of three basil genotypes as a function of harvesting. J Agric Food Chem 2008; 56(2): 380-5.
[http://dx.doi.org/10.1021/jf0725629] [PMID: 18095647]
[19]
Zeighami H, Valadkhani F, Shapouri R, Samadi E, Haghi F. Virulence characteristics of multidrug resistant biofilm forming Acinetobacter baumannii isolated from intensive care unit patients. BMC Infect Dis 2019; 19(1): 629.
[http://dx.doi.org/10.1186/s12879-019-4272-0] [PMID: 31315572]
[20]
Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: A systematic review and network meta-analysis. J Antimicrob Chemother 2018; 73(1): 22-32.
[http://dx.doi.org/10.1093/jac/dkx368] [PMID: 29069421]
[21]
Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep 2021; 48(10): 6987-98.
[http://dx.doi.org/10.1007/s11033-021-06690-6] [PMID: 34460060]
[22]
Babapour E, Haddadi A, Mirnejad R, Angaji S-A, Amirmozafari N. Biofilm formation in clinical isolates of nosocomial Acinetobacter baumannii and its relationship with multidrug resistance. Infect Drug Resist 2016; 6(6): 528-33.
[23]
Haghighifar E, Nasr-Esfahani B, Fazeli H. Determination of biofilm formation ability and antibiotic resistance of Acinetobacter baumannii strains isolated from patients with burn wound infection. Majallah-i Danishkadah-i Pizishki-i Isfahan 2019; 37(552): 1280-5.
[24]
Azizi O, Shahcheraghi F, Salimizand H, et al. Molecular analysis and expression of bap gene in biofilm-forming multi-drug-resistant Acinetobacter baumannii. Rep Biochem Mol Biol 2016; 5(1): 62-72.
[PMID: 28070537]
[25]
Thummeepak R, Kongthai P, Leungtongkam U, Sitthisak S. Distribution of virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter baumannii clinical isolates. Int Microbiol 2016; 19(2): 121-9.
[PMID: 27845499]
[26]
Gallant CV, Daniels C, Leung JM, et al. Common β‐lactamases inhibit bacterial biofilm formation. Mol Microbiol 2005; 58(4): 1012-24.
[http://dx.doi.org/10.1111/j.1365-2958.2005.04892.x] [PMID: 16262787]
[27]
Gaddy JA, Tomaras AP, Actis LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun 2009; 77(8): 3150-60.
[http://dx.doi.org/10.1128/IAI.00096-09] [PMID: 19470746]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy